论文部分内容阅读
观察乳酸左氧氟沙星注射液治疗肺结核合并下呼道感染的临床疗效。肺结核合并下呼吸道感染64 例患者随机分成两组,分别给予乳酸左氧氟沙星每日0.4g 或头孢噻肟钠每日2.0g 治疗,疗程均为7～14d。结果,乳酸左氧氟沙星组治疗有效率83.9% ,头孢噻肟钠组治疗有效率60.6% ,两组之间有显著性差异(P< 0.05),乳酸左氧氟沙星组疗效优于头孢噻肟钠组。乳酸左氧氟沙星组细菌清除率为81.8% ,头孢噻肟钠组细菌清除率为75% ,两组比较无明显差异。乳酸左氧氟沙星不良反应发生率为4.7% ,但均较轻微,不影响治疗。结果提示,对肺结核合并下呼吸道感染病人可首选乳酸左氧氟沙星治疗。
To observe the clinical efficacy of levofloxacin lactate injection in treating pulmonary tuberculosis complicated with lower respiratory tract infection. Sixty-four patients with pulmonary tuberculosis complicated with lower respiratory tract infection were randomly divided into two groups. The patients were given 0.4g / day of levofloxacin daily or 2.0g / day of cefotaxime sodium daily for 7-14 days. Results The effective rate of levofloxacin lactate group was 83.9%, and that of cefotaxime sodium group was 60.6%. There was significant difference between the two groups (P <0.05). The efficacy of levofloxacin lactate group was better than that of cefotaxime sodium group. The bacterial clearance rate was 81.8% in levofloxacin lactate group and 75% in cefotaxime sodium group. There was no significant difference between the two groups. The incidence of adverse reactions of levofloxacin lactate was 4.7%, but were minor, does not affect the treatment. The results suggest that patients with pulmonary tuberculosis complicated with lower respiratory tract infection may be the preferred treatment of levofloxacin lactate.